^
Association details:
| Biomarker: | ER-CCDC170 fusion |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) + lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance
Published date:
08/08/2020
Excerpt:
More important, breast cancer cells expressing ectopic or endogenous ESR1-CCDC170 are highly sensitive to treatment regimens combining endocrine agents with the HER2 inhibitor lapatinib and/or the SRC inhibitor dasatinib.
DOI:
10.1186/s13058-020-01325-3
